Lesson
Read the Morphology and Protect the Diagnosis
Dermatophytes infect keratinized tissue, but site names do not prove an organism. Morphology, distribution, exposure, and a properly collected specimen turn pattern recognition into a defensible diagnosis.
- Keratin sites
- Active border
- KOH preparation
- Culture and molecular testing
- Tinea incognito
Name the infected compartment
Describe before treating
Match specimen to the question
Protect mimics and treatment-altered disease
Start with tissue and pattern
Inspect skin, hair, and nails separately. Record border activity, scale, central change, follicular involvement, alopecia, maceration, fissures, nail debris, distribution, symptoms, and treatment history.
Use testing when it changes care
Collect scale from an active edge for potassium hydroxide microscopy. Culture, histopathology, or molecular methods can answer organism, resistance, nail, hair, atypical, or treatment-failure questions. A negative poor specimen does not exclude disease.
Protect the differential
Nummular eczema, psoriasis, contact dermatitis, pityriasis rosea, erythrasma, candidiasis, bacterial infection, and other disorders can imitate tinea. Prominent scrotal involvement, absent scale, unusual pain, systemic illness, or failure should reopen the diagnosis.
Recognize treatment-altered disease
Corticosteroids can reduce redness and itch while fungus spreads. Ask about every cream, including combination products, and look for altered borders, atrophy, striae, pustules, or unexpectedly extensive disease.
Quick check
Checking for saved practice…
Lesson
Treat Body and Groin Disease as Connected Systems
Localized corporis and cruris often respond to topical therapy, but feet, nails, clothing, contacts, animals, and corticosteroid exposure can sustain recurrence.
- Tinea corporis
- Tinea cruris
- Topical boundary
- Reservoir sites
- Failure audit
Define extent and competing diagnoses
Continue beyond early symptom relief
Find autoinoculation reservoirs
Verify before escalating
Treat localized skin disease completely
Use an appropriate labeled topical antifungal over the lesion and beyond its visible edge for the full product-specific duration. Continue as directed even when itch and redness improve early.
Distinguish the groin differential
Tinea cruris often affects upper inner thighs and may spare the scrotum. Candidiasis, erythrasma, inverse psoriasis, irritant disease, and sexually associated emerging dermatophytes require different reasoning.
Find the reservoir
Inspect feet and nails, review household and animal exposure, launder contaminated clothing and towels, reduce shared items, and address moisture and friction. Autoinoculation can reseed treated skin.
Audit before escalating
Confirm diagnosis, product, amount, application boundary, frequency, duration, adherence, reinfection, follicular disease, host factors, and steroid exposure before changing therapy or assuming resistance.
Quick check
Checking for saved practice…
Lesson
Treat the Feet and Interrupt Recurrence
Interdigital, moccasin, and inflammatory patterns require attention to the whole foot, footwear, moisture, nails, barrier injury, and bacterial complications.
- Interdigital disease
- Moccasin scale
- Fissures
- Footwear
- Cellulitis risk
Choose therapy and vehicle
Reduce the fungal environment
Prevent bacterial entry
Separate cellulitis from tinea
Map the entire foot
Inspect between every toe, the sole, sides, heel, and nails. Maceration, diffuse scale, vesicles, odor, fissures, dystrophic nails, pain, and drainage change the differential and urgency.
Treat environment and skin
Dry carefully between toes, change socks, ventilate and rotate footwear, avoid sharing shoes or towels, and use sandals in communal wet areas. An unmedicated drying powder does not treat fungus. A medicated antifungal powder can treat labeled skin disease when used for its full course; distinguish active ingredient from vehicle.
Protect high-risk feet
Diabetes, neuropathy, vascular disease, edema, immune compromise, and limited self-care increase harm from fissures and delayed infection. Avoid caustic self-treatment and arrange foot care when inspection or application is unsafe.
Escalate bacterial warning signs
Spreading redness, warmth, severe pain, pus, fever, lymphangitis, or systemic illness suggests bacterial complication. Fungal treatment alone is not adequate for cellulitis or an infected ulcer.
Quick check
Checking for saved practice…
Lesson
Separate Candida from Other Fold Disease
Intertrigo names inflammation in a fold. Candida is one cause, favored by moisture, friction, antibiotics, metabolic disease, immune compromise, and occlusion.
- Satellite pustules
- Moisture
- Erythrasma
- Inverse psoriasis
- Driver review
Support candidal disease
Do not equate fold rash with Candida
Treat the local environment
Review metabolic and immune drivers
Read candidal clues
A moist beefy erythematous fold eruption with peripheral satellite papules or pustules supports Candida, but testing can help when morphology, recurrence, or treatment response conflicts.
Keep competing diagnoses visible
Dermatophyte infection, erythrasma, bacterial intertrigo, inverse psoriasis, irritant friction, and allergic contact disease can overlap. Wood lamp examination, KOH, culture, distribution, and exposure history answer different questions.
Match Candida treatment to its indication
Nystatin cream 100,000 units/g is an option for susceptible cutaneous Candida, commonly applied twice daily until healing according to the prescription. It is not a substitute for a dermatophyte treatment. Skin cream must not be used in the mouth, eyes, or vagina. Persistent irritation or failure warrants reassessment and, when appropriate, repeat diagnostic testing.
Change the fold environment
Gently dry, reduce friction and occlusion, use breathable materials, manage incontinence or drainage, and create a sustainable skin-protection plan. Do not place absorbent material that remains wet against skin.
Do not label every inflamed nail fold Candida
Paronychia is nail-fold inflammation, not a synonym for onychomycosis. Chronic disease can follow wet work, irritants, nail cosmetics, cuticle injury, or inflammatory skin disease; yeast or bacterial infection may complicate it. Protect the barrier, reduce the identified exposure, and assess suspected infection. Clinician-directed anti-inflammatory treatment may be appropriate for established inflammatory paronychia. Pus, marked pain, or spreading inflammation needs evaluation rather than automatic antifungal or antibiotic self-treatment.
Investigate recurrence
Review glycemia, obesity, antibiotics, corticosteroids, immune status, and local anatomy when episodes are frequent, severe, or refractory. Recurrence can reveal a systemic or environmental driver.
Quick check
Checking for saved practice…
Lesson
Use Topical Antifungals as Drug Delivery Systems
Allylamines and azoles interrupt ergosterol biology at different enzymes. Active ingredient, organism, infected tissue, formulation, application boundary, and duration must align.
- Squalene epoxidase
- CYP51
- Vehicle
- Application technique
- Local reactions
Block squalene epoxidase
Block lanosterol demethylation
Move drug across the right surface
Make exposure executable
Map the pathways
Allylamines such as terbinafine inhibit squalene epoxidase. Azoles inhibit lanosterol 14 alpha demethylase, also called fungal CYP51. Both disrupt ergosterol biology through different targets.
Match spectrum and tissue
Dermatophyte and Candida likelihood, hair or nail involvement, lesion extent, inflammation, and prior exposure determine whether a topical drug is sufficient. Scalp follicle and nail matrix disease usually need a different exposure strategy.
Treat the vehicle as clinical
Creams fit many dry or mildly moist surfaces. Solutions, sprays, or gels can spread through hair or larger areas. Unmedicated powders reduce moisture; medicated antifungal powders can also deliver treatment. Choose around fissures, maceration, dexterity, stinging, coverage, and patient preference.
Read the exact cream label
For Lamisil AT terbinafine 1% cream in people age 12 years or older, the labeled course is once daily for 1 week for body or groin ringworm, twice daily for 1 week between the toes, and twice daily for 2 weeks on the soles or sides of the feet. Ask a clinician for children under 12. These instructions do not transfer automatically to another formulation or brand.
Keep skin treatment in its compartment
This terbinafine cream is not labeled for nails, scalp, or vaginal yeast infection. A short skin course cannot substitute for a nail-specific preparation or systemic treatment of infected hair.
Write operational instructions
Specify clean and dry preparation, exact area, extension beyond the border, frequency, duration, missed-dose response, hand hygiene, adverse effects, and follow-up. Use teach-back rather than relying on a product name.
Quick check
Checking for saved practice…
Lesson
Choose the Ingredient, Formulation, and Course
An antifungal brand name does not identify one interchangeable regimen. Read the active ingredient, site, age limit, and directions on the exact product.
- Clotrimazole
- Butenafine
- Luliconazole
- Medicated powder
- Tolnaftate
- Undecylenic acid
One brand may contain different antifungals
Confirm the formulation reaches the infection
Luliconazole age limits vary by site
Finish the labeled course; reassess failure
Clotrimazole cream uses a longer course
The reviewed OTC clotrimazole 1% cream label directs a thin layer twice daily: 4 weeks for athlete's foot or body ringworm, 2 weeks for jock itch. Children under 2 need clinician direction. Stop and obtain advice for irritation or lack of improvement at those intervals. It is ineffective for scalp or nail infection.
Butenafine offers two toe-web schedules
The reviewed Lotrimin Ultra butenafine 1% applicator product is labeled for interdigital athlete's foot at age 12 or older: twice daily for 1 week or once daily for 4 weeks. Its effectiveness on soles or foot sides is unknown. Children under 12 need clinician advice. Do not extend this specific package's indication or schedule to every product sold under the same brand.
Luliconazole has site-specific pediatric limits
Prescription luliconazole 1% cream (Luzu) is used once daily for 2 weeks for interdigital tinea pedis, or 1 week for corporis or cruris. Apply a thin layer to affected skin and approximately 1 inch of surrounding skin. The labeled age threshold is 2 years for corporis but 12 years for pedis and cruris. Local application reactions can occur; keep it out of the eyes, mouth, and vagina.
A medicated powder can be treatment
Miconazole nitrate 2% antifungal powder is a drug delivery form, not just a drying aid. A reviewed label specifies twice-daily application for 4 weeks for athlete's foot or ringworm and 2 weeks for jock itch. Follow the dispensed label, keep it away from eyes, and do not use it as a scalp or nail cure. Read the actual Drug Facts panel on barrier products. Baza Antifungal lists miconazole nitrate 2% as its active antifungal; petrolatum is an inactive ingredient. Its jock-itch directions are a thin layer twice daily for 2 weeks, with clinician review if irritation occurs or improvement is absent. Children under 2 years need clinician direction; this skin cream does not treat scalp or nail infection.
Tolnaftate is another labeled skin option
The reviewed tolnaftate 1% cream directions are twice daily for 4 weeks for pedis or corporis and 2 weeks for cruris. Under age 2, use requires clinician direction. If irritation occurs or the condition persists, reassess rather than extending treatment indefinitely. Its skin indication does not establish efficacy for nails or scalp.
Separate ketoconazole cream from foam
The reviewed prescription ketoconazole 2% cream uses once-daily treatment for 2 weeks for candidal skin disease, corporis or cruris, and 6 weeks for pedis. Its pediatric safety and effectiveness are not established. Ketoconazole 2% foam instead has a seborrheic dermatitis indication in immunocompetent patients age 12 and older; fungal-infection efficacy is not established for that foam. Do not substitute the foam because its active ingredient matches the cream.
Understand the steroid combination limitation
Clotrimazole/betamethasone cream is labeled for inflammatory tinea at age 17 and older, but routine steroid-antifungal combinations are discouraged in ringworm care. If specifically prescribed, the label uses twice daily for 1 week for corporis/cruris or 2 weeks for pedis; reassess absent improvement then. Maximum durations are 2 and 4 weeks, respectively, with no more than 45 g/week and no occlusive dressing. Avoid diaper use. Steroid exposure can cause atrophy, striae and adrenal suppression; reduced redness alone is not cure.
A nail-shaped applicator does not establish a nail indication
The reviewed undecylenic acid 25% liquid is labeled twice daily for 4 weeks for athlete's foot or body ringworm. Despite a brush that can reach around nails, its directions explicitly state that it is ineffective on nails or scalp. Choose by the infection being treated, not the shape of the bottle or applicator.
Quick check
Checking for saved practice…
Lesson
Treat Hair and Scalp Through the Follicle
Tinea capitis infects the hair shaft and follicle. Systemic therapy is required, while adjunctive shampoo and contact measures reduce transmission but do not replace oral treatment.
- Broken hairs
- Kerion
- Griseofulvin
- Systemic exposure
- Contact control
Identify the scalp pattern
Protect against scarring
Reach the infected follicle
Reduce shared exposure
Recognize the scalp patterns
Scale, alopecia, broken hairs, black dots, pruritus, lymph nodes, and inflammatory plaques can occur. A tender boggy kerion, drainage, pain, fever, or potential scarring needs prompt clinician assessment.
Use systemic therapy
Topical creams do not penetrate the infected hair shaft and follicle sufficiently. Oral griseofulvin, terbinafine, or another clinician-selected systemic antifungal depends on organism, age, formulation, safety, and local practice.
Dose griseofulvin by formulation
Microsize and ultramicrosize products are not milligram-for-milligram substitutes. Review weight, food-dependent absorption, liver disease, porphyria, lupus, reproductive risk, alcohol, warfarin, contraceptive reliability, and duration.
Check the dose against the formulation and source
Specialist capitis regimens can exceed older US label doses. Texas Children's published referral guidance uses microsize griseofulvin 20 to 25 mg/kg/day for about 2 months, versus ultramicrosize 10 to 15 mg/kg/day. These are clinician-directed regimens; the reviewed US microsize label instead lists 10 mg/kg/day for children older than 2 years, and the ultramicrosize label lists about 3.3 mg/lb/day. Document the selected regimen and its source rather than treating these doses as interchangeable.
Calculate the prescribed suspension dose
For an illustrative 20 kg child prescribed microsize griseofulvin 20 mg/kg once daily: 20 kg times 20 mg/kg = 400 mg/day. A 125 mg/5 mL suspension contains 25 mg/mL, so 400 divided by 25 = 16 mL per daily dose. Shake the bottle and measure with an oral syringe. Confirm the prescription and formulation before using the example; it does not determine treatment for an individual child.
Turn precautions into counseling
Griseofulvin is contraindicated in pregnancy, porphyria, and hepatocellular failure. It can reduce warfarin effect and estrogen-containing contraceptive effectiveness; arrange anticoagulation monitoring and reliable pregnancy prevention. Avoid alcohol, address photosensitivity, and review lupus and prolonged-treatment monitoring. The label advises waiting at least 6 months after treatment before fathering a child.
Control transmission
Adjunctive antifungal shampoo may reduce surface spores. Avoid shared combs, hats, bedding, clippers, and towels, identify symptomatic contacts and animal sources, and follow local school and public-health recommendations.
Quick check
Checking for saved practice…
Lesson
Confirm and Treat Nail Disease on the Nail Timeline
Onychomycosis means fungal nail infection; tinea unguium refers specifically to dermatophyte nail infection, not to the name of an organism. Trauma, psoriasis, and other nail disorders can mimic it. Confirm fungus, select therapy through extent and risk, and wait for healthy nail growth before judging appearance.
- Diagnostic confirmation
- Subungual debris
- Oral terbinafine
- Liver safety
- Nail growth
Exclude nonfungal dystrophy
Justify oral or topical therapy
Use systemic treatment safely
Separate slow growth from failure
Confirm before systemic treatment
Obtain a quality nail clipping or subungual specimen for KOH, culture, histopathology, or another suitable method. Sampling strategy depends on the nail pattern and prior antifungal exposure.
Choose through disease and patient
Number of nails, matrix involvement, thickness, pain, function, diabetes, circulation, immune status, liver disease, interactions, adherence, cost, and patient goals determine oral, topical, debridement, or referral strategy.
Use oral terbinafine safely
Current labeling uses 250 mg once daily for 6 weeks for fingernail and 12 weeks for toenail dermatophyte onychomycosis. Confirm disease, exclude chronic or active liver disease, obtain baseline liver tests, and arrange periodic liver monitoring as the label recommends.
Keep alternative oral therapy in context
Fluconazole is an off-label US option for nail infection when standard agents are unsuitable; the April 2026 British Association of Dermatologists leaflet also identifies it as an alternative. The prescriber must select an organism-appropriate regimen and review renal function, pregnancy, interactions, QT risk, and liver safety. Griseofulvin has a nail indication but is generally less useful because of long courses and lower efficacy. Posaconazole has been studied for nails but is not FDA-approved for this indication; historical trial results do not make it a routine replacement for terbinafine or itraconazole. Refractory or unusual-organism cases need specialist reassessment rather than automatic escalation to a broader azole.
Set the right response clock
Healthy nail grows slowly. Photograph or measure proximal clear growth and treat coexisting tinea pedis. Stop oral terbinafine and seek prompt assessment for signs of liver injury, progressive severe rash, or taste or smell loss. New depressive symptoms also require clinical review.
Quick check
Checking for saved practice…
Lesson
Deliver Nail Treatment for the Full Growth Cycle
A nail product needs sustained contact with the diseased nail. Confirm the organism and extent, then choose a preparation the patient can apply consistently for many months.
- Ciclopirox 8%
- Efinaconazole 10%
- Tavaborole 5%
- Application technique
- Long treatment course
Daily coats, weekly removal, professional nail care
Daily for 48 weeks; cover nail and surrounding structures
Daily for 48 weeks; nail surface and beneath tip
Container discard date is not the course end date
Distinguish nail lacquer from skin cream
Ciclopirox 8% nail lacquer is a different preparation from 0.77% skin products. Its labeled role is mild to moderate fingernail or toenail disease due to T rubrum without lunula involvement in immunocompetent patients. Pediatric safety is extrapolated for age 12 and older; pediatric clinical trials were not conducted.
Make the lacquer regimen workable
Apply daily, usually at bedtime, over the affected nail and 5 mm of adjacent skin; reach the exposed underside when possible. Leave coats in place between applications and remove them with alcohol weekly. Wait 8 hours before bathing. Treatment may take 48 weeks and includes professional removal of unattached infected nail, as often as monthly. Diabetes or reduced sensation requires an individualized trimming plan. Avoid nail cosmetics and flames.
Do not assume additive nail benefit
The ciclopirox lacquer label does not recommend concomitant systemic antifungals because the effect of that combination has not been studied. Do not automatically add lacquer to an oral regimen. Discuss modest complete-clearance rates and the long daily commitment before choosing treatment.
Use efinaconazole over the whole treatment surface
Efinaconazole 10% solution (Jublia) treats dermatophyte toenail disease in patients age 6 and older. Apply daily for 48 weeks. Cover the nail, folds, nail bed, hyponychium, and accessible undersurface with the brush. Wait at least 10 minutes after washing or bathing, and apply to clean, dry nails. Persistent irritation, ingrown nail, blistering, or pain warrants review; keep the flammable product away from heat and flames. The effect of nail cosmetics on efficacy is untested.
Distinguish tavaborole from an azole
Tavaborole 5% solution is an oxaborole that interferes with fungal protein synthesis through a tRNA synthetase. For dermatophyte toenail infection at age 6 or older, apply daily over the full nail surface and beneath its tip for 48 weeks. Allow it to dry. Watch for peeling, redness, dermatitis, or an ingrown nail. Keep it away from flames. Check the dispensed package instructions: the reviewed Alembic bottle must be discarded 3 months after the dropper is inserted.
Make a long course feasible
Count the nails requiring treatment, assess reach and hand function, demonstrate the applicator, check supply and cost, and plan refills. A bottle's discard date is different from the treatment end date. Record proximal healthy growth and treatment tolerability; early persistence of old discolored nail does not alone establish failure.
Quick check
Checking for saved practice…
Lesson
Separate Oral Regimens and Interaction Pathways
Choosing an oral antifungal means choosing a specific dosing schedule, absorption requirement, interaction profile, and surveillance plan.
- Terbinafine CYP2D6
- Itraconazole capsules
- Pulse versus continuous
- Heart failure
- Absorption
Review interacting medicines and liver risk
Heart failure excludes nail treatment
Verify site and calendar
Address acid suppression; do not substitute oral solution
Do not substitute oral ketoconazole for topical treatment
Ketoconazole tablets are not indicated for skin dermatophyte infection, onychomycosis, or Candida infection. Serious liver injury, including fatal cases, and dangerous drug interactions make them an inappropriate substitute for a topical ketoconazole product in this setting.
Review terbinafine's actual interaction pathway
Terbinafine inhibits CYP2D6. Review susceptible antidepressants, beta blockers, and class IC antiarrhythmics; monitoring or a dose adjustment of the interacting drug may be needed. Do not apply an azole CYP3A4-inhibitor rule to every systemic antifungal. Use at creatinine clearance 50 mL/min or lower is inadequately studied and needs an individualized decision.
Keep itraconazole schedules site-specific
Conventional 100 mg itraconazole capsules: toenail disease, with or without fingernail involvement, uses 200 mg daily for 12 weeks. Fingernails alone use 200 mg twice daily for 7 days, then 21 days off, then another 7-day course.
Check cardiac and interaction exclusions
Do not use itraconazole for onychomycosis with current or previous heart failure or ventricular dysfunction. Review its contraindicated combinations, including simvastatin and lovastatin. CYP3A4 interactions can cause serious toxicity, including arrhythmias. Consider liver monitoring; stop and seek evaluation for liver-injury or heart-failure symptoms.
Match absorption to the preparation
Take conventional capsules whole after a full meal. Acid suppression can reduce absorption and requires a management plan. Capsules and oral solution are not interchangeable.
Address reproductive planning before nail treatment
Do not use itraconazole for nail disease during pregnancy or when planning pregnancy. For patients who can become pregnant, its label requires effective contraception during treatment and for 2 months afterward; begin on menstrual day 2 or 3.
Quick check
Checking for saved practice…
Lesson
Investigate Failure and Emerging Resistance
Current CDC guidance highlights T indotineae and terbinafine-resistant T rubrum. Severe, extensive, atypical, or verified treatment-resistant disease may need specialized identification and susceptibility testing.
- T indotineae
- Resistant T rubrum
- TMVII
- Susceptibility testing
- Stewardship
Exclude ordinary failure
Consider emerging dermatophytes
Use specialized laboratories
Reduce pressure and delay
Audit common failure first
Reconfirm diagnosis, infected compartment, product, dose, duration, adherence, application, steroid exposure, reinfection, contacts, host factors, and specimen quality. Most failure mechanisms are not proven resistance.
Recognize emerging patterns
T indotineae can produce severe widespread inflammatory plaques and may resist terbinafine. TMVII can produce persistent genital, buttock, or facial lesions linked to intimate contact. Unlike the resistant strains, TMVII is generally not antimicrobial resistant; current CDC evidence supports oral terbinafine, although some patients need itraconazole and prolonged clinician-directed treatment. Terbinafine-resistant T rubrum is also a concern.
Use the right laboratory
Routine laboratories may not distinguish T indotineae from related complexes. Culture, molecular identification, and antifungal susceptibility testing may require a reference laboratory and dermatology, infectious-disease, or public-health coordination.
Protect stewardship
Avoid unneeded steroid-antifungal combinations, incomplete treatment, serial ineffective courses, and unverified systemic exposure. Document treatment precisely and counsel contacts and hygiene without stigmatizing transmission.
Quick check
Checking for saved practice…
Lesson
Close the Loop Across Risk, Interaction, and Life Stage
Topical and systemic antifungal decisions change with age, pregnancy, lactation, liver disease, diabetes, circulation, immune status, drug interactions, access, and ability to complete treatment.
- Product-specific risk
- Pregnancy narrative
- Interaction review
- Teach-back
- Response targets
Individualize exposure
Name the actual systemic product
Confirm safe execution
Define the next decision
Use narrative reproductive evidence
Do not use obsolete pregnancy letters. Review human and animal evidence, disease burden, route, exposure area, timing, alternatives, lactation, fertility, and shared goals for the exact product.
Reconcile systemic interactions
Azoles, terbinafine, and griseofulvin affect different enzymes and organ risks. Review prescription drugs, nonprescription products, supplements, alcohol, warfarin, CYP substrates, seizure therapy, contraception, hepatotoxic drugs, and QT risk when relevant.
Adapt to host risk
Children need weight and formulation checks. Diabetes, neuropathy, vascular disease, immune compromise, and liver disease change urgency and safety. Limited dexterity, vision, housing, laundry, or medication access can undermine an otherwise correct plan.
Define success and failure
Set a reassessment interval and track border activity, scale, itch, new lesions, hair or nail growth, contacts, adverse effects, adherence, and test results. State exactly when to stop treatment and seek help.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 50 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- CDC Treatment of Ringworm
- CDC Emerging Ringworm Clinician Brief
- CDC Clinical Overview of Ringworm
- DailyMed Terbinafine Tablets
- DailyMed Ultramicrosize Griseofulvin
- DailyMed Lamisil AT 1% Cream
- DailyMed Ciclopirox 8% Nail Lacquer
- DailyMed Efinaconazole (Jublia)
- DailyMed Tavaborole 5% Solution
- DailyMed Itraconazole Capsules
- DailyMed Nystatin Cream
- Texas Children's Tinea Capitis Referral Guidance
- DailyMed Microsize Griseofulvin Suspension
- AAFP Tinea Management Pitfalls (2014)
- DailyMed Clotrimazole 1% Cream
- DailyMed Lotrimin Ultra Applicator
- DailyMed Luzu Cream
- DailyMed Miconazole Powder Label
- DailyMed Tolnaftate Cream
- DailyMed Undecylenic Acid Liquid
- DailyMed Ketoconazole 2% Cream
- DailyMed Ketoconazole Foam
- DailyMed Clotrimazole/Betamethasone Cream
- British Association of Dermatologists: Chronic Paronychia
- DailyMed Baza Antifungal Cream
- DailyMed Ketoconazole Tablets: Boxed Warning
- BAD Fungal Nail Infections (April 2026)
- BAD Onychomycosis Guideline (2014): Alternative Therapy Evidence
- Diflucan US Prescribing Information
- DailyMed Posaconazole: Indications and Formulations